Once a diagnosis is made, each individual's treatment is based on an individual’s clinical condition. Hematopoietic stem cell transplant is a possible treatment of this condition but its effectiveness is unproven and may be accompanied by severe and potentially fatal hemorrhage. It was previously thought magnesium supplementation was a promising potential treatment for<unk> . One of the consequences of loss of MAGT1 function is a decreased level of unbound intracellular Mg2+. This decrease leads to loss of expression of an immune cell receptor called NKG2D, which is involved in EBV-immunity. Mg2+ supplementation in some tests restored NKG2D expression and other functions that are abnormal in patients with<unk> . Early evidence suggested continuous oral magnesium threonate supplementation was safe and well tolerated. A randomized, double-blind, placebo-controlled, crossover study was conducted to evaluate the use of Mg2+ as a treatment for<unk> . In vitro magnesium supplementation experiments failed to significantly rescue NKG2D expression in patients with<unk>  and the clinical trial was stopped. Therefore, magnesium supplementation is unlikely to be an effective therapeutic option in<unk> . Investigators at the National Institute of Allergy and Infectious<unk> s at the US National Institutes of Health currently have clinical protocols to study new approaches to the diagnosis and treatment of this disorder.
XMEN disease
Fanconi–Bickel syndrome
Abruzzo–Erickson syndrome
Treacher Collins syndrome
Hajdu–Cheney syndrome
LIG4 syndrome
Fanconi syndrome
Fazio–Londe disease